A Comprehensive Transcriptional Signature in Pancreatic Ductal Adenocarcinoma Reveals New Insights into the Immune and Desmoplastic Microenvironments

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 Jun 10

PMID 37296850

Authors

Irene Perez-Diez

Zoraida Andreu

Marta R Hidalgo

Carla Perpina-Clerigues

Lucia Fantin

Antonio Fernandez-Serra

Maria de la Iglesia-Vaya

Jose A Lopez-Guerrero

Francisco Garcia-Garcia

Affiliations

Soon will be listed here.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) prognoses and treatment responses remain devastatingly poor due partly to the highly heterogeneous, aggressive, and immunosuppressive nature of this tumor type. The intricate relationship between the stroma, inflammation, and immunity remains vaguely understood in the PDAC microenvironment. Here, we performed a meta-analysis of stroma-, and immune-related gene expression in the PDAC microenvironment to improve disease prognosis and therapeutic development. We selected 21 PDAC studies from the Gene Expression Omnibus and ArrayExpress databases, including 922 samples (320 controls and 602 cases). Differential gene enrichment analysis identified 1153 significant dysregulated genes in PDAC patients that contribute to a desmoplastic stroma and an immunosuppressive environment (the hallmarks of PDAC tumors). The results highlighted two gene signatures related to the immune and stromal environments that cluster PDAC patients into high- and low-risk groups, impacting patients' stratification and therapeutic decision making. Moreover, , , , , and immune genes are related to the prognosis of PDAC patients for the first time.

Citing Articles

MR Molecular Image Guided Treatment of Pancreatic Cancer with Targeted ECO/miR-200c Nanoparticles in Immunocompetent Mouse Tumor Models.

Laney V, Hall R, Yuan X, Hampson E, Halle A, Yeung G Pharm Res. 2024; 41(9):1811-1825.

PMID: 39198318 PMC: 11436418. DOI: 10.1007/s11095-024-03762-7.

Role and mechanism of IRF9 in promoting the progression of rheumatoid arthritis by regulating macrophage polarization via PSMA5.

Guan Y, Li X, Yang H, Xu S, Shi L, Liu Y Heliyon. 2024; 10(15):e35589.

PMID: 39170377 PMC: 11336755. DOI: 10.1016/j.heliyon.2024.e35589.

Nanotechnology-Based Strategy for Enhancing Therapeutic Efficacy in Pancreatic Cancer: Receptor-Targeted Drug Delivery by Somatostatin Analog.

Gu X, Majumder J, Taratula O, Kuzmov A, Garbuzenko O, Pogrebnyak N Int J Mol Sci. 2024; 25(10).

PMID: 38791582 PMC: 11122428. DOI: 10.3390/ijms25105545.

Targeted Nanoparticle-Based Diagnostic and Treatment Options for Pancreatic Cancer.

Gu X, Minko T Cancers (Basel). 2024; 16(8).

PMID: 38672671 PMC: 11048786. DOI: 10.3390/cancers16081589.

Single-Cell Analysis Differentiates the Effects of p53 Mutation and p53 Loss on Cell Compositions of Oncogenic Kras-Driven Pancreatic Cancer.

Sun X, Yang D, Chen Y Cells. 2023; 12(22).

PMID: 37998349 PMC: 10670612. DOI: 10.3390/cells12222614.

References

Park W, Chawla A, OReilly E . Pancreatic Cancer: A Review. JAMA. 2021; 326(9):851-862. PMC: 9363152. DOI: 10.1001/jama.2021.13027. View

Zhang H, Pan Y, Cheung M, Cao M, Yu C, Chen L . LAMB3 mediates apoptotic, proliferative, invasive, and metastatic behaviors in pancreatic cancer by regulating the PI3K/Akt signaling pathway. Cell Death Dis. 2019; 10(3):230. PMC: 6408539. DOI: 10.1038/s41419-019-1320-z. View

Lei X, Chen G, Li J, Wen W, Gong J, Fu J . Comprehensive analysis of abnormal expression, prognostic value and oncogenic role of the hub gene FN1 in pancreatic ductal adenocarcinoma bioinformatic analysis and experiments. PeerJ. 2021; 9:e12141. PMC: 8428264. DOI: 10.7717/peerj.12141. View

Weinstein J, Collisson E, Mills G, Mills Shaw K, Ozenberger B, Ellrott K . The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013; 45(10):1113-20. PMC: 3919969. DOI: 10.1038/ng.2764. View

Atkinson S, Andreu Z, Vicent M . Polymer Therapeutics: Biomarkers and New Approaches for Personalized Cancer Treatment. J Pers Med. 2018; 8(1). PMC: 5872080. DOI: 10.3390/jpm8010006. View

Whatcott C, Diep C, Jiang P, Watanabe A, LoBello J, Sima C . Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer. Clin Cancer Res. 2015; 21(15):3561-8. PMC: 4526394. DOI: 10.1158/1078-0432.CCR-14-1051. View

Goonesekere N, Wang X, Ludwig L, Guda C . A meta analysis of pancreatic microarray datasets yields new targets as cancer genes and biomarkers. PLoS One. 2014; 9(4):e93046. PMC: 3989178. DOI: 10.1371/journal.pone.0093046. View

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

Di Federico A, Mosca M, Pagani R, Carloni R, Frega G, De Giglio A . Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes. Cancers (Basel). 2022; 14(10). PMC: 9139656. DOI: 10.3390/cancers14102429. View

10.

Gonzalez-Titos A, Hernandez-Camarero P, Barungi S, Marchal J, Kenyon J, Peran M . Trypsinogen and chymotrypsinogen: potent anti-tumor agents. Expert Opin Biol Ther. 2021; 21(12):1609-1621. DOI: 10.1080/14712598.2021.1922666. View

11.

Jahny E, Yang H, Liu B, Jahnke B, Lademann F, Knosel T . The G Protein-Coupled Receptor RAI3 Is an Independent Prognostic Factor for Pancreatic Cancer Survival and Regulates Proliferation via STAT3 Phosphorylation. PLoS One. 2017; 12(1):e0170390. PMC: 5256936. DOI: 10.1371/journal.pone.0170390. View

12.

Wang H, Sha W, Liu Z, Chi C . Effect of chymotrypsin C and related proteins on pancreatic cancer cell migration. Acta Biochim Biophys Sin (Shanghai). 2011; 43(5):362-71. DOI: 10.1093/abbs/gmr022. View

13.

Zhuang H, Chen X, Dong F, Zhang Z, Zhou Z, Ma Z . Prognostic values and immune suppression of the S100A family in pancreatic cancer. J Cell Mol Med. 2021; 25(6):3006-3018. PMC: 7957204. DOI: 10.1111/jcmm.16343. View

14.

Zhou X, Liu Y, Hu M, Wang M, Liu X, Huang L . Relaxin gene delivery modulates macrophages to resolve cancer fibrosis and synergizes with immune checkpoint blockade therapy. Sci Adv. 2021; 7(8). PMC: 7888957. DOI: 10.1126/sciadv.abb6596. View

15.

Liu Q, Zhao H, Guo Y, Zhang K, Shang F, Liu T . Bioinformatics-Based Analysis: Noncoding RNA-Mediated COL10A1 Is Associated with Poor Prognosis and Immune Cell Infiltration in Pancreatic Cancer. J Healthc Eng. 2022; 2022:7904982. PMC: 9467764. DOI: 10.1155/2022/7904982. View

16.

Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z . clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation (Camb). 2021; 2(3):100141. PMC: 8454663. DOI: 10.1016/j.xinn.2021.100141. View

17.

Rodolosse A, Chalaux E, Adell T, Hagege H, Skoudy A, Real F . PTF1alpha/p48 transcription factor couples proliferation and differentiation in the exocrine pancreas [corrected]. Gastroenterology. 2004; 127(3):937-49. DOI: 10.1053/j.gastro.2004.06.058. View

18.

Henriksen A, Dyhl-Polk A, Chen I, Nielsen D . Checkpoint inhibitors in pancreatic cancer. Cancer Treat Rev. 2019; 78:17-30. DOI: 10.1016/j.ctrv.2019.06.005. View

19.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

20.

Dong C, Dang D, Zhao X, Wang Y, Wang Z, Zhang C . Integrative Characterization of the Role of IL27 In Melanoma Using Bioinformatics Analysis. Front Immunol. 2021; 12:713001. PMC: 8558420. DOI: 10.3389/fimmu.2021.713001. View